Access Pharmaceuticals receives FDA marketing clearance of ProctiGard
Boston-based Ziopharm, Intrexon tackle immuno-oncology drugs in expanded partnership
Allergan announces earnings and restructuring/layoffs, while still fighting Valeant
AbbVie and Shire - latest on the merger
Visit our sites for b2b sales and banking employees:
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Dragon Pharmaceutical | 1 | 7 | 600 % |
| Pacific Biosciences | 1 | 6 | 500 % |
| AmerisourceBergen | 1 | 5 | 400 % |
| Actelion | 1 | 5 | 400 % |
| Heritage Pharmaceuticals | 1 | 5 | 400 % |
| GSK | 11 | 49 | 345 % |
| JNJ | 5 | 21 | 320 % |
| Derma Sciences | 3 | 12 | 300 % |
| Aventis | 2 | 8 | 300 % |
| Cosmo Pharma | 1 | 3 | 200 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| ChemoCentryx | 1 | 9 | 800 % |
| BioSpecifics Technologies | 2 | 17 | 750 % |
| Tekmira Pharmaceuticals | 4 | 34 | 750 % |
| XenoPort | 3 | 22 | 633 % |
| Vascular Solutions | 5 | 36 | 620 % |
| Access Pharmaceuticals | 5 | 35 | 600 % |
| Warner Chilcott | 1 | 7 | 600 % |
| Alliqua BioMedical | 3 | 19 | 533 % |
| Ziopharm | 10 | 61 | 510 % |
| Viamet | 2 | 12 | 500 % |